Skip to content

US · ORGO · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Organogenesis Holdings Inc. (ORGO) intrinsic value and stock valuation

$0.77as of 2026-11-21 · Mkt cap 239.33M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Organogenesis Holdings Inc. DCF and intrinsic value

InvestorsCraft values ORGO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ORGO’s statements →

Organogenesis Holdings Inc. Graham Number

Graham Number: $4.74d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Canton, MA 02021 organogenesis.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$563M+10.7% 5y CAGRd
20162025
Net income
$37M+16.5% 5y CAGRd
20162025
Free cash flow
-$-24.46M
20152025
Total equity
$433.9M+25.1% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$563M$482M$433.1M$450.9M$467.4M
Operating income$55.9M-$-1.28M$12.5M$22.3M$72.2M
Net income$37M$860K$4.95M$15.5M$94.2M
EPSd$284.3K$6.53K$37.3K$117.3K$704.8K
Operating cash flow-$-10.31M$14.2M$30.9M$24.9M$62M
Capital expenditure-$-14.15M-$-10.03M-$-24.36M-$-33.9M-$-31.22M
Free cash flow-$-24.46M$4.18M$6.55M-$-9.04M$30.8M
Total assets$598.7M$497.9M$460M$449.4M$443.3M
Total debt$132.8M$43.3M$119.4M$123.8M$132.3M
Net debt$39.2M-$-92.26M$15M$21.3M$18.4M
Total equity$433.9M$385.3M$278.7M$265.7M$241.3M
Cash and short-term investments$93.7M$135.6M$104.3M$102.5M$113.9M
Income statement
20252024202320222021
Revenue$563M$482M$433.1M$450.9M$467.4M
Cost of revenue$137.5M$115.7M$106.5M$105M$114.2M
Gross profit$425.5M$366.3M$326.7M$345.9M$353.2M
Research and development expenses$44.5M$50.3M$44.4M$39.8M$30.7M
Selling, general and administrative expenses$326.2M$294.5M$269.8M$283.8M$250.2M
Other expenses-$-1.14M$22.8M$0.00$0.00$0.00
Operating expenses$369.6M$367.6M$314.1M$323.6M$280.9M
Cost and expenses$507.2M$483.3M$420.6M$428.6M$395.1M
Interest income$2.28M$0.00$0.00$0.00$0.00
Interest expense$0.00$1.54M$2.19M$2.01M$7.24M
Depreciation and amortization$26.9M$17M$23.5M$18M$16.7M
Ebitda$73.9M$15.8M$36M$40.3M$87M
Operating income$55.9M-$-1.28M$12.5M$22.3M$72.2M
Total other income/expenses, net-$-8.9M-$-1.52M-$-2.13M-$-2.02M-$-9.13M
Income before tax$47M-$-2.81M$10.4M$20.3M$63.1M
Income tax expense$9.94M-$-3.67M$5.45M$4.75M-$-31.12M
Net income$37M$860K$4.95M$15.5M$94.2M
Weighted average shares outstanding$126.7M$131.7M$131.2M$130.1M$128.3M
Weighted average diluted shares outstanding$130.3M$131.7M$132.8M$132.4M$133.7M
Balance sheet
20252024202320222021
Cash and short-term investments$93.7M$135.6M$104.3M$102.5M$113.9M
Net receivables$217.5M$109.9M$82M$89.5M$82.5M
Inventory$29.6M$26.2M$28.3M$24.8M$25M
Total current assets$362.2M$285.9M$225M$222.6M$227M
Property, plant and equipment, net$159.5M$126.2M$156.4M$145.7M$128.3M
Goodwill and intangible assets$37.9M$41.2M$44.6M$49.6M$54.5M
Long-term investments$0.00$0.00$15.9M$0.00$0.00
Total non-current assets$236.5M$211.9M$235M$226.8M$216.3M
Total assets$598.7M$497.9M$460M$449.4M$443.3M
Accounts payable$32M$28.9M$30.7M$32.3M$29.3M
Short-term debt$18.6M$9.11M$19.7M$16.3M$14.6M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$100.1M$77.5M$80.5M$75M$82.7M
Long-term debt$114.2M$34.2M$99.6M$107.6M$117.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$64.7M$35.1M$100.9M$108.7M$119.2M
Capital lease obligations$63.5M$43.3M$53.1M$53M$58.9M
Total liabilities$164.8M$112.6M$181.4M$183.7M$201.9M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-3.08M-$-40.11M-$-40.97M-$-45.3M-$-60.83M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$433.9M$385.3M$278.7M$265.7M$241.3M
Total investments$0.00$0.00$15.9M$0.00$0.00
Total debt$132.8M$43.3M$119.4M$123.8M$132.3M
Net debt$39.2M-$-92.26M$15M$21.3M$18.4M
Cash flow statement
20252024202320222021
Net income$37M$860K$4.95M$15.5M$94.9M
Depreciation and amortization$26.9M$17M$23.5M$10.7M$16.7M
Stock-based compensation$13.3M$10.6M$9M$6.55M$3.86M
Change in working capital-$-132.38M-$-48.89M-$-18.07M-$-34.08M-$-39.29M
Accounts receivable-$-115.8M-$-31.8M$5.54M-$-8.77M-$-30.23M
Inventory-$-17.91M-$-6.2M$6.58M-$-9.41M-$-9.3M
Accounts payable-$-530K-$-2.37M-$-110K$3.26M$3.85M
Net cash provided by operating activities-$-10.31M$14.2M$30.9M$24.9M$62M
Investments in property, plant and equipment-$-14.15M-$-10.03M-$-24.36M-$-33.9M-$-31.22M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-14.15M-$-10.03M-$-24.36M-$-33.9M-$-31.22M
Common stock issued$160K$0.00$0.00$0.00$2.2M
Common stock repurchased$0.00-$-25.48M$0.00$0.00$0.00
Dividends paid$0.00-$-1.8M$0.00$0.00$0.00
Net cash used for financing activities-$-17.36M$27.6M-$-5.5M-$-2.2M-$-1.04M
Net change in cash-$-41.82M$31.8M$1.05M-$-11.24M$29.7M
Cash at end of period$94.3M$136.2M$104.3M$103.3M$114.5M
Operating cash flow-$-10.31M$14.2M$30.9M$24.9M$62M
Capital expenditure-$-14.15M-$-10.03M-$-24.36M-$-33.9M-$-31.22M
Free cash flow-$-24.46M$4.18M$6.55M-$-9.04M$30.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Organogenesis Holdings Inc.

        Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

        CEO
        Gary S. Gillheeney
        Employees
        854
        Beta
        1.33

        Explore

        Frequently asked questions

        What is the intrinsic value of Organogenesis Holdings Inc. (ORGO)?

        InvestorsCraft does not currently publish an intrinsic value for ORGO. How the IC value is calculated.

        Is ORGO undervalued?

        InvestorsCraft does not publish an undervaluation signal for ORGO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.